Yissum's mission is to commercialize technologies developed at the Hebrew University of Jerusalem (HUJI) for societal benefit and to support research. Yissum protects intellectual property from HUJI researchers' inventions, licenses them to industry, and returns revenues through royalties to support further research. Some key points include: Yissum is responsible for over 7,700 patents and 566 licenses that have generated over $2 billion in annual product sales, including drugs to treat Alzheimer's (Exelon) and cancer (Doxil). Yissum has also helped launch 74 spin-off companies and its innovations account for 40% of available projects for technology licensing in Israel.
This document summarizes Israel's life sciences industry and investment opportunities. Israel has a strong life sciences sector, with the highest civilian R&D spending as a percentage of GDP globally. Key sectors include biotechnology, pharmaceuticals, and medical devices. Israel has developed blockbuster drugs and medical technologies. It also has a robust stem cell research sector. Foreign companies have established R&D centers in Israel to take advantage of the innovative ecosystem and government support programs. The Investment Promotion Center encourages investors to establish operations in Israel to access these opportunities.
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive function. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms.
The document appears to be a survey assessing supernatural abilities. It contains 10 questions with answer options on a scale of 1 to 5. The questions gauge abilities like focus, premonitions, belief in the afterlife, mind reading, feelings in certain places, encounters with spirits, warmth of touch, decision making abilities, thinking of someone and connecting with them, and having multiple personalities. The results section provides analysis for different score ranges. A score of 10-22 means the person lacks supernatural abilities and is highly skeptical. A score of 23-37 means the person senses phenomena but is too skeptical to develop abilities fully. A score of 38-50 means the person is aware of and believes in their abilities due to strong faith.
Yissum's mission is to commercialize technologies developed at the Hebrew University of Jerusalem (HUJI) for societal benefit and to support research. Yissum protects intellectual property from HUJI researchers' inventions, licenses them to industry, and returns revenues through royalties to support further research. Some key points include: Yissum is responsible for over 7,700 patents and 566 licenses that have generated over $2 billion in annual product sales, including drugs to treat Alzheimer's (Exelon) and cancer (Doxil). Yissum has also helped launch 74 spin-off companies and its innovations account for 40% of available projects for technology licensing in Israel.
Forest fires can destroy homes, animals, and land. Children should be taught fire safety and proper camping behavior. If a forest fire threatens your village, evacuate with important items and animals. Most forest fires are caused by human actions like improper campfires or fireworks, so take precautions like parking away from trees and buying home insurance if near forests.
- The document discusses biotechnology research and the use of public and privately-held intellectual property (IP) in research projects. It presents a model to analyze the minimum expected cost of a research project based on characteristics of the organism, attributes, and proximity to existing IP.
- Key factors in the expected cost include the difficulty of the organism/attributes, the effectiveness and proximity of available IP, and IP prices. The model can be used to examine how IP prices and new innovations affect technology choices and substitution between public and private IP.
- Hypotheses explored include how IP use varies for different types of projects, organisms, and sectors based on these factors. The model captures important aspects of cumulative nature and assembly process of
This document summarizes Israel's life sciences industry and investment opportunities. Israel has a strong life sciences sector, with the highest civilian R&D spending as a percentage of GDP globally. Key sectors include biotechnology, pharmaceuticals, and medical devices. Israel has developed blockbuster drugs and medical technologies. It also has a robust stem cell research sector. Foreign companies have established R&D centers in Israel to take advantage of the innovative ecosystem and government support programs. The Investment Promotion Center encourages investors to establish operations in Israel to access these opportunities.
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive function. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms.
The document appears to be a survey assessing supernatural abilities. It contains 10 questions with answer options on a scale of 1 to 5. The questions gauge abilities like focus, premonitions, belief in the afterlife, mind reading, feelings in certain places, encounters with spirits, warmth of touch, decision making abilities, thinking of someone and connecting with them, and having multiple personalities. The results section provides analysis for different score ranges. A score of 10-22 means the person lacks supernatural abilities and is highly skeptical. A score of 23-37 means the person senses phenomena but is too skeptical to develop abilities fully. A score of 38-50 means the person is aware of and believes in their abilities due to strong faith.
Yissum's mission is to commercialize technologies developed at the Hebrew University of Jerusalem (HUJI) for societal benefit and to support research. Yissum protects intellectual property from HUJI researchers' inventions, licenses them to industry, and returns revenues through royalties to support further research. Some key points include: Yissum is responsible for over 7,700 patents and 566 licenses that have generated over $2 billion in annual product sales, including drugs to treat Alzheimer's (Exelon) and cancer (Doxil). Yissum has also helped launch 74 spin-off companies and its innovations account for 40% of available projects for technology licensing in Israel.
Forest fires can destroy homes, animals, and land. Children should be taught fire safety and proper camping behavior. If a forest fire threatens your village, evacuate with important items and animals. Most forest fires are caused by human actions like improper campfires or fireworks, so take precautions like parking away from trees and buying home insurance if near forests.
- The document discusses biotechnology research and the use of public and privately-held intellectual property (IP) in research projects. It presents a model to analyze the minimum expected cost of a research project based on characteristics of the organism, attributes, and proximity to existing IP.
- Key factors in the expected cost include the difficulty of the organism/attributes, the effectiveness and proximity of available IP, and IP prices. The model can be used to examine how IP prices and new innovations affect technology choices and substitution between public and private IP.
- Hypotheses explored include how IP use varies for different types of projects, organisms, and sectors based on these factors. The model captures important aspects of cumulative nature and assembly process of
This document summarizes Israel's life sciences industry and aims to promote investment in Israel. It highlights that Israel has a strong innovation ecosystem in life sciences, with the highest civilian R&D spending as a percentage of GDP. Israel also leads in areas like medical device and biopharma patents per capita. The document outlines Israel's competitive advantages and provides statistics on economic growth, exports, unemployment and foreign investment. It summarizes the main sectors and technologies within Israel's life sciences industry, including blockbuster drugs developed, major therapeutic areas and examples of medical device and biotechnology innovations. The conclusion encourages investors to establish operations in Israel and take advantage of government support programs.
UBS West Coast Life Science Bus Tour presented an overview of Thermo Fisher Scientific. [1] It discussed the company's two business segments: Analytical Technologies and Laboratory Products and Services. [2] New products were highlighted in areas like sample preparation, analysis, and data interpretation. [3] Technologies like mass spectrometry, RNAi, and the Exactive were discussed as enabling key applications in areas such as proteomics, stem cell research, and screening.
UBS hosted a life science bus tour for investors at Thermo Fisher Scientific in San Jose, CA. The agenda included a company overview, technology overview, and factory tour. Thermo Fisher Scientific is a $10.5 billion company with 34,000 employees serving over 350,000 customers in 150 countries. It has two business segments: analytical technologies focused on scientific instruments; and laboratory products and services focused on consumables and services. The company discussed opportunities in areas like stem cell research, protein research using mass spectrometry, and RNAi technology, demonstrating new products in these areas. The tour concluded with an overview of Thermo Fisher's San Jose facility and product lines.
Yissum is the technology transfer company of the Hebrew University of Jerusalem. It works to commercialize university technologies for societal benefit and to support research. Some key points:
- Yissum has transferred many technologies resulting in $1.3 billion in annual sales and has filed over 6,100 patents.
- It generates revenues through licensing and sponsored research that support the Hebrew University's $110 million research budget.
- Examples of successful spin-offs include Mobileye, an advanced driver assistance system, and DOXIL, a cancer treatment drug that generated $430 million in sales in 2008.
Fra scienza e impresa: l’innovazione nei processi produttivi –Esempi di innov...Italeaf S.p.A.
L'Istituto Italiano di Tecnologia (IIT) è un centro statale di ricerca scientifica, governato da una fondazione di diritto privato, creato per l'avanzamento della scienza in Italia. La sede scientifica è a Genova Bolzaneto, mentre quella amministrativa si trova a Roma. Centri distaccati di ricerca sono inoltre attivi in diverse città (undici in Italia e due Boston negli Stati Uniti), in collaborazione con diverse università.
The Institute of Molecular Biology & Biotechnology investigates topics like gene expression under stress and differentiation, the nervous system, aging and neurodegeneration, and protein trafficking. It develops technologies like insect control systems, DNA microchips, new antibiotics, and gene silencing for crop protection. The institute also promotes interdisciplinary research and industry collaborations.
Genopole is a biotechnology park and cluster located near Paris, France. It was established in 1998 to promote the creation and development of biotech companies through providing:
- Office and lab space across 83,000 square meters
- Shared technical platforms and equipment across 15 facilities
- Business support services and incubation programs
- Connections to nearby academic and research institutions
Genopole has supported the growth of over 80 companies and projects, generating over 1,000 jobs and €207 million in funding. It aims to further strengthen the regional biotech cluster through expanding facilities like GMP production centers.
The Life Science Product Manager's Toolkitprothenberg
A discussion about market research tools that can optimize each stage of the new product development process. Prepared by BioInformatics LLC exclusively for life science product and marketing managers.
Dr peterdonnellybiobusinessei letterkennythreesixty
The document discusses the development of medical device technologies in Ireland. It describes Bluescope Medical Technologies, which was founded as a spin-out of Queen's University Belfast in 2004 and later acquired by Axellis. It also describes BioBusiness, an organization that supports the life and health technology sector in Ireland through programs, initiatives, and projects to facilitate collaboration between academia, clinical partners, and businesses.
Innovation holds the key to remain competitive in this era of globalization. With resources dwindling and competition increasing, it is now crucial to develop an ecosystem for nurturing innovations in farming and scientific community. The session will explore the factors which are needed for encouraging innovations and identify key success parameters that can enhance innovation in the Indian context.
The document discusses several agribusiness incubation centers (BPDs) under the Network of Indian Agri Business Incubators (NIABI) project. It provides details on the infrastructure and facilities available at various BPDs hosted by research and academic institutes across India. These include office and lab spaces, pilot plants, libraries and specialized equipment available for startups in domains like agriculture, dairy, fisheries and food processing. The BPDs have successfully incubated 75 ventures so far, commercialized 44 technologies, and generated revenue of 23 million rupees within 18 months.
The document announces a conference on biobanking to be held on February 4-5, 2010 in London. It will examine trends in the biobanking industry and address challenges in areas like ethics, regulation, and cost-effectiveness. Key speakers will discuss developing biobanks, patient involvement, and data protection. Attendees can network with leaders from pharma, biotech, healthcare, and regulatory agencies. The conference aims to provide an in-depth understanding of opportunities and advancements in biobanking.
The document discusses findings from a study on patent trends in nanomaterials. Some key findings include:
1) Patent filings in nanomaterials have consistently outpaced other nanotech subfields and now account for around 40% of nanotechnology patents. Emerging materials like graphene show increased activity.
2) Nanomaterials patents show high interrelation, possibly indicating blocking patents and thickets, reflecting the complexity of developing and applying nanomaterials.
3) Asian countries, especially China, are rising strengths in nanomaterials patenting accompanied by Chinese acquisitions of foreign companies and technologies.
4) Respondents identified blocking patents and patent thickets as key intellectual property issues for nanotechnology.
Catalonia has a large biotechnology sector concentrated around Barcelona, with over 1,150 entities including 268 biotech companies employing over 29,000 people. Catalonia contributes 29.4% of Spain's total biotech turnover of €15.6 billion annually from local initiatives despite making up only 20.5% of Spanish biotech companies. Catalonia has strong academic and research institutions that support its biotech industry, including 12 universities (10 offering life sciences), 150 research centers (60 in life sciences), 21 CSIC centers, and 215 hospitals.
The Offshore Wind Infrastructure Application Lab (OWI-Lab) was established to support innovation in offshore wind energy technology through testing and research infrastructure. It focuses on technological issues crucial for Belgian companies in this growing industry, such as withstanding harsh offshore conditions and reducing operations and maintenance costs. The lab has made investments totaling 5.5 million Euros in state-of-the-art testing facilities, including a large climate chamber that can test components up to 150 tons from -60°C to +60°C. The next steps include expanding the lab and establishing an offshore test site in Flanders to further support the offshore wind industry.
Quentin Tannock (Managing Director of CambridgeIP) presented at NanoMaterials Conference 2011 on the topic of 'Nanomaterials trends: Evidence from scientific literature'.
The presentation provides an overview, methodology, context and some conclusions of an recent nanomaterials IPLandscape conducted by CambridgeIP researchers.
The document provides an overview of Israel's Technological Incubators Program. It discusses how the program supports innovative startups through various incubators located around Israel. The program provides funding, facilities, expertise and other resources to help projects develop technologies and form startups. It highlights the government's significant involvement and discusses privatization efforts to strengthen the incubators. Statistics are given on the numbers of projects supported, fields of activity, and success metrics like private investments raised. Several high-profile Israeli tech companies that graduated from the incubator program are profiled as success stories.
The document discusses various topics related to nanotechnology including basic concepts, commercial activities, drug delivery, implantable materials, sensory aids, surgical tools, detection technologies, and potential futures. It provides size comparisons to illustrate the nanoscale and overviews applications in areas like biopharmaceutics, tissue engineering, medical devices, and more. Various challenges and opportunities are presented along with a large list of companies working in nanotechnology.
This document summarizes Israel's life sciences industry and aims to promote investment in Israel. It highlights that Israel has a strong innovation ecosystem in life sciences, with the highest civilian R&D spending as a percentage of GDP. Israel also leads in areas like medical device and biopharma patents per capita. The document outlines Israel's competitive advantages and provides statistics on economic growth, exports, unemployment and foreign investment. It summarizes the main sectors and technologies within Israel's life sciences industry, including blockbuster drugs developed, major therapeutic areas and examples of medical device and biotechnology innovations. The conclusion encourages investors to establish operations in Israel and take advantage of government support programs.
UBS West Coast Life Science Bus Tour presented an overview of Thermo Fisher Scientific. [1] It discussed the company's two business segments: Analytical Technologies and Laboratory Products and Services. [2] New products were highlighted in areas like sample preparation, analysis, and data interpretation. [3] Technologies like mass spectrometry, RNAi, and the Exactive were discussed as enabling key applications in areas such as proteomics, stem cell research, and screening.
UBS hosted a life science bus tour for investors at Thermo Fisher Scientific in San Jose, CA. The agenda included a company overview, technology overview, and factory tour. Thermo Fisher Scientific is a $10.5 billion company with 34,000 employees serving over 350,000 customers in 150 countries. It has two business segments: analytical technologies focused on scientific instruments; and laboratory products and services focused on consumables and services. The company discussed opportunities in areas like stem cell research, protein research using mass spectrometry, and RNAi technology, demonstrating new products in these areas. The tour concluded with an overview of Thermo Fisher's San Jose facility and product lines.
Yissum is the technology transfer company of the Hebrew University of Jerusalem. It works to commercialize university technologies for societal benefit and to support research. Some key points:
- Yissum has transferred many technologies resulting in $1.3 billion in annual sales and has filed over 6,100 patents.
- It generates revenues through licensing and sponsored research that support the Hebrew University's $110 million research budget.
- Examples of successful spin-offs include Mobileye, an advanced driver assistance system, and DOXIL, a cancer treatment drug that generated $430 million in sales in 2008.
Fra scienza e impresa: l’innovazione nei processi produttivi –Esempi di innov...Italeaf S.p.A.
L'Istituto Italiano di Tecnologia (IIT) è un centro statale di ricerca scientifica, governato da una fondazione di diritto privato, creato per l'avanzamento della scienza in Italia. La sede scientifica è a Genova Bolzaneto, mentre quella amministrativa si trova a Roma. Centri distaccati di ricerca sono inoltre attivi in diverse città (undici in Italia e due Boston negli Stati Uniti), in collaborazione con diverse università.
The Institute of Molecular Biology & Biotechnology investigates topics like gene expression under stress and differentiation, the nervous system, aging and neurodegeneration, and protein trafficking. It develops technologies like insect control systems, DNA microchips, new antibiotics, and gene silencing for crop protection. The institute also promotes interdisciplinary research and industry collaborations.
Genopole is a biotechnology park and cluster located near Paris, France. It was established in 1998 to promote the creation and development of biotech companies through providing:
- Office and lab space across 83,000 square meters
- Shared technical platforms and equipment across 15 facilities
- Business support services and incubation programs
- Connections to nearby academic and research institutions
Genopole has supported the growth of over 80 companies and projects, generating over 1,000 jobs and €207 million in funding. It aims to further strengthen the regional biotech cluster through expanding facilities like GMP production centers.
The Life Science Product Manager's Toolkitprothenberg
A discussion about market research tools that can optimize each stage of the new product development process. Prepared by BioInformatics LLC exclusively for life science product and marketing managers.
Dr peterdonnellybiobusinessei letterkennythreesixty
The document discusses the development of medical device technologies in Ireland. It describes Bluescope Medical Technologies, which was founded as a spin-out of Queen's University Belfast in 2004 and later acquired by Axellis. It also describes BioBusiness, an organization that supports the life and health technology sector in Ireland through programs, initiatives, and projects to facilitate collaboration between academia, clinical partners, and businesses.
Innovation holds the key to remain competitive in this era of globalization. With resources dwindling and competition increasing, it is now crucial to develop an ecosystem for nurturing innovations in farming and scientific community. The session will explore the factors which are needed for encouraging innovations and identify key success parameters that can enhance innovation in the Indian context.
The document discusses several agribusiness incubation centers (BPDs) under the Network of Indian Agri Business Incubators (NIABI) project. It provides details on the infrastructure and facilities available at various BPDs hosted by research and academic institutes across India. These include office and lab spaces, pilot plants, libraries and specialized equipment available for startups in domains like agriculture, dairy, fisheries and food processing. The BPDs have successfully incubated 75 ventures so far, commercialized 44 technologies, and generated revenue of 23 million rupees within 18 months.
The document announces a conference on biobanking to be held on February 4-5, 2010 in London. It will examine trends in the biobanking industry and address challenges in areas like ethics, regulation, and cost-effectiveness. Key speakers will discuss developing biobanks, patient involvement, and data protection. Attendees can network with leaders from pharma, biotech, healthcare, and regulatory agencies. The conference aims to provide an in-depth understanding of opportunities and advancements in biobanking.
The document discusses findings from a study on patent trends in nanomaterials. Some key findings include:
1) Patent filings in nanomaterials have consistently outpaced other nanotech subfields and now account for around 40% of nanotechnology patents. Emerging materials like graphene show increased activity.
2) Nanomaterials patents show high interrelation, possibly indicating blocking patents and thickets, reflecting the complexity of developing and applying nanomaterials.
3) Asian countries, especially China, are rising strengths in nanomaterials patenting accompanied by Chinese acquisitions of foreign companies and technologies.
4) Respondents identified blocking patents and patent thickets as key intellectual property issues for nanotechnology.
Catalonia has a large biotechnology sector concentrated around Barcelona, with over 1,150 entities including 268 biotech companies employing over 29,000 people. Catalonia contributes 29.4% of Spain's total biotech turnover of €15.6 billion annually from local initiatives despite making up only 20.5% of Spanish biotech companies. Catalonia has strong academic and research institutions that support its biotech industry, including 12 universities (10 offering life sciences), 150 research centers (60 in life sciences), 21 CSIC centers, and 215 hospitals.
The Offshore Wind Infrastructure Application Lab (OWI-Lab) was established to support innovation in offshore wind energy technology through testing and research infrastructure. It focuses on technological issues crucial for Belgian companies in this growing industry, such as withstanding harsh offshore conditions and reducing operations and maintenance costs. The lab has made investments totaling 5.5 million Euros in state-of-the-art testing facilities, including a large climate chamber that can test components up to 150 tons from -60°C to +60°C. The next steps include expanding the lab and establishing an offshore test site in Flanders to further support the offshore wind industry.
Quentin Tannock (Managing Director of CambridgeIP) presented at NanoMaterials Conference 2011 on the topic of 'Nanomaterials trends: Evidence from scientific literature'.
The presentation provides an overview, methodology, context and some conclusions of an recent nanomaterials IPLandscape conducted by CambridgeIP researchers.
The document provides an overview of Israel's Technological Incubators Program. It discusses how the program supports innovative startups through various incubators located around Israel. The program provides funding, facilities, expertise and other resources to help projects develop technologies and form startups. It highlights the government's significant involvement and discusses privatization efforts to strengthen the incubators. Statistics are given on the numbers of projects supported, fields of activity, and success metrics like private investments raised. Several high-profile Israeli tech companies that graduated from the incubator program are profiled as success stories.
The document discusses various topics related to nanotechnology including basic concepts, commercial activities, drug delivery, implantable materials, sensory aids, surgical tools, detection technologies, and potential futures. It provides size comparisons to illustrate the nanoscale and overviews applications in areas like biopharmaceutics, tissue engineering, medical devices, and more. Various challenges and opportunities are presented along with a large list of companies working in nanotechnology.
1. Yissum’s Mission
To promote the transfer of Hebrew University technology
for the benefit of society, while maximizing returns to
support research, education and scientific excellence
Yissum = Hebrew for ‘application’
2. The Technology Transfer Process
Yissum protects the IP
and commercializes it
HUJI
researchers
The Industry
discover new
partner pays
Research Money invention &
Yissum for
submit
the license to
disclosure
use its IP
Yissum pays royalties to
the researchers and HUJI
3. A Heritage of Excellence
43% of Israel’s
biotechnology 30% of all Israeli
>1/3 of PhD research academic scientific
students in Israel research
23,000 students
1,000 researchers
(staff members)
1,600 Post-Graduate
students in
biotechnology
5 affiliated hospitals
6 Campuses
3,500 Research >100 Research
projects
centers
Over 400 Researchers
in applied sciences
4. Areas of Expertise
Pharmacology and
Agriculture
Medicine
Brain Research Engineering and
Computer Science
Nanoscience and
Cleantech
Advanced Materials
Education Veterinary
5. 48 Years of Transferring Technologies
7,736 patents
2,212 inventions
566 licenses
74 spin-offs
Products based on Hebrew University technologies &
commercialized by Yissum generate over $2 billion in annual sales
6. Israel Tech Transfer Organization
Yissum
40%
Yeda
21%
Yissum’s innovations
Yissum - reflect 40% of the total
a leading number of projects
member of the available for licensing
ITTN *
by Israeli technology
Technion transfer companies.
13%
Bar Ilan
5%
Ben
Ramot TLV Gurion
8% Carmel
Medical Mor Hadasit 1% 4%
Center 2% 5%
1%
* By number of available technologies
7. Intellectual Property
Materials & 2011 Snapshot
Chemistry Agriculture, 150 new inventions
20% Food &
Nutrition,
154 new patent
Cleantech applications
14% 54 new patents granted
Micro & Opto
Electronics
A variety of 5% Intellectual Property at HU
new Computer
Yissum owns all IP
inventions Science & developed at HU
Engeneering Researchers receive
11%
40-60% of revenues
Life Science &
Biotechnology
50%
8. Projects Available for Licensing 2012
Materials & Agriculture,
Nanotechnology Food &
15% Nutrition,
Cleantech
13%
Applied physics
4%
Over 400
Computer
technologies Science &
Engeneering
Life Science & 13%
Biotechnology
53% Education
1%
Homeland
Security
1%
12. Success Stories - Exelon
Exelon®
For Treatment of Symptoms Alzheimer’s Disease and
Dementia
Prof. Marta Weinstock-Rosin
Department of Pharmacology, Faculty of Medicine
The Hebrew University of Jerusalem
2010 sales over $1 Billion
13. Success Stories - Doxil
DOXIL® - Doxorubicin HCI liposome injection
Alza’s Lead Product for Oncology
Prof. Yechezkel Barenholz
Department of Biochemistry, Faculty of Medicine
The Hebrew University of Jerusalem
Prof. Alberto Gabizon
Hadassah University Hospital Jerusalem
2010 sales over $500 million
14. Success Stories - Tomatoes
Long Shelf Life Tomatoes
The world’s most popular cocktail hybrids for year
round greenhouse production
Prof. Nachum Kedar
Prof. Haim Rabinowich
Department of Field Crops, Vegetables and Genetics:
Faculty of Agriculture, Food and Environmental
Sciences
The Hebrew University Rehovot Campus
15. Success Stories - Peppers
Hybrid Peppers
Breeding of Blocky type pepper hybrids for growing under
mild winter conditions. Market leader in Spain, Israel &
Mexico In collaboration with Zeraim Gedera (Fully owned
by Syngenta)
Dr. Yonatan Elkind
Department of Field Crops, Vegetables and Genetics:
Faculty of Agriculture, Food and Environmental Sciences
The Hebrew University Rehovot Campus
16. Success Stories - Mobileye
Mobileye
Advanced vision based driver assistance system for
accident prevention
Prof. Amnon Shashua
Computer Science & Engineering, Faculty of Science
The Hebrew University of Jerusalem
2010 Valuation of $740 million
(Investment by Goldman Sachs & others)
17. Products on the Market
The innovative cationic Periochip - slow drug
emulsion for the treatment release for periodentitis
of dry eye symptoms
Prof. Michael Friedman &
Prof. Simon Benita Prof. Doron Steinberg
Bioresorbable
Supra-Vir - Acyclovir cream for Adhesion Barrier
HSV topical treatment reduces the severity
Moisturizing
of post-operative
Prof. Elka Touitou Eye Drops
cardiac adhesions
Prof. Shabtay
Dikstein Prof. Daniel Cohn